SCHEMBL1492094

SCHEMBL1492094

CCS(=O)(=O)N(Cc1ccc(OC)cc1)c1ccc(F)c(N)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.44
APLNR P35414 5/20 0.41
ACLY P53396 1/20 0.38
CNR1 P21554 2/20 0.38
PTGER1 P34995 1/20 0.37
TAS2R14 Q9NYV8 3/20 0.36
ALDH1A1 P00352 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
BCL2A1 Q16548 2/20 0.35
LMNA P02545 2/20 0.35
NR3C1 P04150 1/20 0.35
PGR P06401 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9930750 0.94 CNR2 (0.42) CNR2APLNRACLYCNR1PTGER1
SCHEMBL1492035 0.89 APLNR (0.43) CNR2APLNRACLYCNR1TAS2R14
SCHEMBL12497941 0.88 CNR2 (0.39) CNR2APLNRACLYCNR1PTGER1
SCHEMBL1462111 0.84 APLNR (0.41) CNR2APLNRACLYCNR1TAS2R14
SCHEMBL9930518 0.84 CNR2 (0.42) CNR2APLNRACLYCNR1TAS2R14
SCHEMBL12497894 0.82 APLNR (0.39) CNR2APLNRCNR1TAS2R14ALDH1A1
SCHEMBL22842899 0.81 SMN1; SMN2 (0.33) CNR2APLNRACLYALDH1A1HTT
SCHEMBL1460926 0.79 CNR2 (0.40) CNR2APLNRACLYCNR1TAS2R14
SCHEMBL12499269 0.77 APLNR (0.39) CNR2APLNRACLYCNR1TAS2R14
SCHEMBL22831927 0.75 KMT2A (0.38) ACLYALDH1A1HTTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102712646-A RAF inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC 2012-10-03 CN disclosed
EP-2470538-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2012-07-04 EP disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
WO-2011025940-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 WO disclosed
WO-2011025940-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF CNR2 4318/4885APLNR 4487/4885ACLY 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.